Cancer
A study published in the Journal of Obstetrics and Gynaecology Research has reported a groundbreaking case of brain metastasis treatment using a combination of lenvatinib and pembrolizumab. The 43-year-old patient, who had endometrial cancer with mismatch repair deficiency, developed multiple brain metastases despite chemotherapy. However, after receiving stereotactic radiotherapy, followed
Cancer research
Recent research from Koc University Hospital in Istanbul, Turkiye, has shed light on the effectiveness of a modified port implantation technique in improving intraperitoneal chemotherapy (IPCT) outcomes for patients with stage III and IV ovarian cancers. The study found that patients who received 7 cycles or more of IPCT using
Cancer research
A new report discusses the effectiveness of polatuzumab vedotin combined with rituximab and bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma. Research conducted at the Chiba Cancer Center Research Institute in Japan found that patients treated with this therapy showed improved overall survival rates and were more
Cancer research
Researchers at Qingdao University have published a study on the application of chemotherapy using a combination of platinum and taxane agents in treating ovarian cancer. The study reveals that the abnormality of the nuclear pore complex (NPC) leads to nuclear envelope destruction and disrupts transmembrane transport, causing abnormal substance exchange.
Cancer metastasis
The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial, a large-scale, Phase III clinical study investigating the effect of adding chemotherapy to current standard treatments for men with advanced prostate cancer. The trial aims to determine whether combining docetaxel, a well-established chemotherapy drug, with hormone therapy and
Chemotherapy
A new approach to treating cancer could revolutionize the field, as researchers have developed a promising new light-based treatment that can target and kill cancer cells while leaving healthy ones unharmed. The treatment, which relies on inexpensive and accessible LED light combined with nanoscopic flakes of tin oxide, has shown
Lymphomas
Researchers at Guangxi Medical University Cancer Hospital have conducted a retrospective study to evaluate the efficacy and safety of zanubrutinib combined with salvage chemotherapy in transplant-ineligible patients with relapsed or refractory (R/R) non-GCB diffuse large B-cell lymphoma (DLBCL). The study found that zanubrutinib combined with either bendamustine and rituximab
Cancer research
A recent study published in the American Journal of Clinical Oncology has found that adjuvant alectinib is a more effective and cost-effective treatment option compared to platinum-based chemotherapy for patients with resectable (stage IB to IIIA) ALK+ non-small cell lung cancer. The study, conducted by researchers at Genentech Inc., evaluated
Cancer research
Research conducted at the Gansu University of Chinese Medicine in People's Republic of China has led to a potential breakthrough in the treatment of non-small cell lung cancer (NSCLC). The study, published in the journal Frontiers in Oncology, investigates the benefits and risks of combining Fuzheng Yiliu Decoction,
Cancer research
Researchers from National Cancer Center Hospital East in Japan have conducted a comprehensive study to evaluate the chronological changes in clinical outcomes associated with oxaliplatin-based doublet chemotherapy and molecular targeted agents in metastatic colorectal cancer patients. The study utilized data from the Aide et Recherche en Cancerologie Digestive (ARCAD) database,
Cancer
Recent research at the First Hospital of Hunan University of Chinese Medicine has shed new light on the potential of metal nanoparticles in cancer diagnosis and treatment. The study, published in the journal Drug Delivery, revealed that metal nanoparticles (MNPs) have unique physicochemical properties that enable precise drug delivery and
Cancer
Researchers at Guangxi Medical University Cancer Hospital have conducted a retrospective study to evaluate the efficacy and safety of zanubrutinib combined with salvage chemotherapy in transplant-ineligible patients with relapsed or refractory (R/R) non-GCB diffuse large B-cell lymphoma (DLBCL). The study found that zanubrutinib combined with either bendamustine and rituximab
